Literature DB >> 3123609

Hypoxanthine transport and metabolism in the central nervous system.

R Spector1.   

Abstract

The mechanisms by which hypoxanthine, the principal purine in plasma and CSF, enters and leaves rabbit brain, choroid plexus, and CSF were investigated in the isolated choroid plexus in vitro and by injecting [14C]hypoxanthine intraventricularly and [3H]hypoxanthine intravenously. The isolated choroid plexus accumulated and extensively metabolized [14C]hypoxanthine; however, 14C was readily released from choroid plexus principally as [14C]-hypoxanthine. After infusion of [3H]hypoxanthine intravenously, [3H]hypoxanthine entered CSF and brain slowly and was converted in brain to nucleotides. Fewer than 5% of the acid-soluble purine nucleotides in brain entered rabbit brain from plasma hypoxanthine (and inosine) per 24 h. After intraventricular injection of [14C]hypoxanthine, the [14C]hypoxanthine was cleared from the CSF into the blood or accumulated by brain and largely converted into 14C-nucleotides. Little [14C]xanthine and no [14C]uric acid or allantoin were formed. These studies show that brain, unlike most other tissues, rapidly recycles hypoxanthine and converts it into purine nucleotides, and not unsalvageable purines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123609     DOI: 10.1111/j.1471-4159.1988.tb03006.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Plasma hypoxanthine: a marker for hypoxic-ischaemic induced periventricular leucomalacia?

Authors:  G A Russell; G Jeffers; R W Cooke
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

2.  Hypoxanthine transport in human glioblastoma cells and effect on cell susceptibility to methotrexate.

Authors:  Wei Kong; Joanne Wang
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

3.  Validation of different microdialysis methods for the determination of unbound steady-state concentrations of theophylline in blood and brain tissue.

Authors:  P Sjöberg; I M Olofsson; T Lundqvist
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

4.  Clinical Targeting of Altered Metabolism in High-Grade Glioma.

Authors:  Andrew J Scott; Costas A Lyssiotis; Daniel R Wahl
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

Review 5.  Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance.

Authors:  Weihua Zhou; Daniel R Wahl
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

6.  Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.

Authors:  Hirohisa Watanabe; Tatsuya Hattori; Akito Kume; Kenichiro Misu; Takashi Ito; Yu Koike; Todd A Johnson; Shigeo Kamitsuji; Naoyuki Kamatani; Gen Sobue
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.